HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jmg.2006.046102v1 44/3/166    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, X. Articles by Chang, A. Search for Related Content PubMed PubMed Citation Articles by Zhang, X. Articles by Chang, A. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Lung Cancer

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer

¹ Division of Biomedical Sciences, Johns Hopkins Singapore, Singapore
² International Medical Centre, Johns Hopkins Singapore, Singapore

Correspondence to:
Dr X Zhang
Division of Biomedical Sciences, Johns Hopkins Singapore, 31 Biopolis Way, #02-01, the Nanos, Singapore 138669, Singapore; xiaozhu{at}imc.jhmi.edu] Frequent overexpression of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva), have been developed and approved by the US Food and Drug Administration for second-line and third-line treatment of advanced NSCLC. Clinical trials have shown considerable variability in the response rate between different patients with NSCLC, which led to the discovery of somatic EGFR-activating mutations. This brief review summarises the discovery and functional consequences of the mutations, their clinicopathological features and significant implications in the treatment and prognosis of NSCLC.

Abbreviations: EGF(R), epidermal growth factor (receptor); NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; SSCP, single-strand conformation polymorphism; TKI, tyrosine kinase inhibitor

This article has been cited by other articles:

				A. Duffy, J. Kortmansky, G. K. Schwartz, M. Capanu, S. Puleio, B. Minsky, L. Saltz, D. P. Kelsen, and E. M. O'Reilly A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma Ann. Onc., September 17, 2007; (2007) mdm441v1. [Abstract] [Full Text] [PDF]